kras g12d degrader arv-806
Generic: KRAS G12D Degrader ARV-806
kras g12d degrader arv-806: 1 clinical trial tracked.
kras g12d degrader arv-806 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about kras g12d degrader arv-806, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Primary endpoint: Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806
Interventionalopen76 enrolledStarted 2025-05Completion 2026-1114 sites · United StatesArvinas Inc.